Harvard Bioscience, Inc. (FRA:HBI)
Germany · Delayed Price · Currency is EUR 0.6350
+0.0050 (0.79%)
At close: Nov 28, 2025
Harvard Bioscience Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 87.37 | 94.14 | 112.25 | 113.34 | 118.9 | 102.1 | Upgrade | |
Revenue Growth (YoY) | -10.60% | -16.14% | -0.96% | -4.68% | 16.46% | -12.12% | Upgrade |
Cost of Revenue | 37.58 | 39.33 | 45.86 | 51.05 | 51.25 | 44.06 | Upgrade |
Gross Profit | 49.79 | 54.81 | 66.39 | 62.29 | 67.65 | 58.04 | Upgrade |
Selling, General & Admin | 37.76 | 43.52 | 46.61 | 49.03 | 47.32 | 41.39 | Upgrade |
Research & Development | 8.97 | 10.41 | 11.76 | 12.33 | 10.8 | 8.69 | Upgrade |
Amortization of Goodwill & Intangibles | 4.43 | 5.26 | 5.53 | 6.12 | 5.84 | 5.71 | Upgrade |
Other Operating Expenses | - | 0.35 | - | - | - | - | Upgrade |
Operating Expenses | 51.16 | 59.53 | 63.9 | 67.48 | 63.96 | 55.79 | Upgrade |
Operating Income | -1.37 | -4.72 | 2.5 | -5.19 | 3.69 | 2.25 | Upgrade |
Interest Expense | -3.41 | -3.21 | -3.59 | -2.55 | -1.54 | -4.83 | Upgrade |
Currency Exchange Gain (Loss) | - | - | - | - | - | -0.5 | Upgrade |
Other Non Operating Income (Expenses) | -0.09 | -0.84 | -0.44 | 0.72 | -1.02 | -0.31 | Upgrade |
EBT Excluding Unusual Items | -4.87 | -8.77 | -1.53 | -7.02 | 1.14 | -3.38 | Upgrade |
Merger & Restructuring Charges | -0.43 | -0.84 | -0.39 | -2.39 | -1.28 | -2.03 | Upgrade |
Gain (Loss) on Sale of Investments | - | -1.59 | -0.63 | - | - | - | Upgrade |
Legal Settlements | - | - | - | 0.23 | - | - | Upgrade |
Other Unusual Items | -0.34 | -0.47 | - | - | - | -1.88 | Upgrade |
Pretax Income | -53.59 | -11.67 | -2.56 | -9.18 | -0.14 | -7.29 | Upgrade |
Income Tax Expense | 0.24 | 0.74 | 0.86 | 0.34 | 0.15 | 0.52 | Upgrade |
Earnings From Continuing Operations | -53.84 | -12.41 | -3.42 | -9.52 | -0.29 | -7.81 | Upgrade |
Net Income | -53.84 | -12.41 | -3.42 | -9.52 | -0.29 | -7.81 | Upgrade |
Net Income to Common | -53.84 | -12.41 | -3.42 | -9.52 | -0.29 | -7.81 | Upgrade |
Shares Outstanding (Basic) | 44 | 44 | 42 | 41 | 40 | 39 | Upgrade |
Shares Outstanding (Diluted) | 44 | 44 | 42 | 41 | 40 | 39 | Upgrade |
Shares Change (YoY) | 2.01% | 2.64% | 2.43% | 2.65% | 4.41% | 2.19% | Upgrade |
EPS (Basic) | -1.22 | -0.28 | -0.08 | -0.23 | -0.01 | -0.20 | Upgrade |
EPS (Diluted) | -1.22 | -0.28 | -0.08 | -0.23 | -0.01 | -0.20 | Upgrade |
Free Cash Flow | 7.44 | -1.2 | 12.24 | -0.44 | 0.07 | 8.18 | Upgrade |
Free Cash Flow Per Share | 0.17 | -0.03 | 0.29 | -0.01 | 0.00 | 0.21 | Upgrade |
Gross Margin | 56.99% | 58.22% | 59.15% | 54.96% | 56.90% | 56.85% | Upgrade |
Operating Margin | -1.57% | -5.01% | 2.22% | -4.58% | 3.10% | 2.21% | Upgrade |
Profit Margin | -61.62% | -13.18% | -3.04% | -8.40% | -0.24% | -7.65% | Upgrade |
Free Cash Flow Margin | 8.52% | -1.28% | 10.90% | -0.39% | 0.06% | 8.01% | Upgrade |
EBITDA | 4.99 | 2.44 | 9.49 | 2.38 | 11.31 | 9.89 | Upgrade |
EBITDA Margin | 5.71% | 2.59% | 8.46% | 2.10% | 9.51% | 9.68% | Upgrade |
D&A For EBITDA | 6.36 | 7.16 | 7 | 7.58 | 7.62 | 7.63 | Upgrade |
EBIT | -1.37 | -4.72 | 2.5 | -5.19 | 3.69 | 2.25 | Upgrade |
EBIT Margin | -1.57% | -5.01% | 2.22% | -4.58% | 3.10% | 2.21% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.